Successful Treatment of Adult-Onset Dermatitis Herpetiformis with Low Dose Naltrexone (Abstract)

The LDN Conference 2021: 4th - 6th June 2021

Up to 29 CME Credits Available + Sponsor, Exhibitor and Advertiser Opportunities.  [More Details]

Successful Treatment of Adult-Onset Dermatitis Herpetiformis with Low Dose Naltrexone

Open Journal of Clinical and Medical Case Reports
August 2017
https://www.researchgate.net/publication/319653170_Successful_treatment_of_adult-onset_dermatitis_herpetiformis_with_low_dose_naltrexone

Dermatitis herpetiformis can be refractory to a gluten free diet in up to 2% of patients. A celiac disease patient with diet refractory dermatitis herpetiformis was treated with low dose naltrexone. Randomized controlled trials showed that this short acting opioid antagonist is effective therapy in Crohn’s disease and fibromyalgia. The patient’s skin lesions were present for 2 years and went into complete remission within 3 months of taking naltrexone. We theorize that gluten-associated antigens activate long-lasting memory B-lymphocyte cells that produce autoimmune antibodies and this may perpetuate dermatitis herpetiformis. Endorphins produced via up-regulation by low dose naltrexone may reduce this B-cell activity.

Keywords: Refractory dermatitis, dermatitis, herpetiformis, naltrexone, celiac